Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Psychiatr Res ; 118: 66-72, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31494376

RESUMEN

BACKGROUND: Schizophrenia (SZ) is associated with cognitive impairment that contributes to disability, but the cognitive dysfunction is relatively refractory to pharmacologic intervention. Though Valproate augmentation is reported to improve psychopathology among patients with SZ, its effects on cognitive functions have not been investigated systematically. METHODS: Using a randomized double blind placebo controlled design, the effects of Valproate or placebo as adjuncts to risperidone (RISP) treatment were evaluated among patients with early course SZ (N = 109). Domains of cognitive function, estimated using the Arabic version of the Penn Computerized Neurocognitive Battery, were the prime outcomes. Clinical severity and social function were secondary outcomes. We also explored the effects of valproate treatment on serological responses to Toxoplama Gondii (TOXO), a putative risk factor for cognitive dysfunction in SZ. RESULTS: There were no significant differences between Valproate and placebo (PLA) treated groups with respect to changes in cognitive functions, positive or negative symptom scores or daily function scores at the beginning and end of the study. No significant Valproate/PLA differences were noted on TOXO serostatus or TOXO-related cognitive dysfunction. CONCLUSION: Valproate treatment may not be beneficial for cognitive dysfunction in SZ or for TOXO infection.


Asunto(s)
Antimaníacos/farmacología , Antipsicóticos/farmacología , Disfunción Cognitiva/tratamiento farmacológico , Risperidona/farmacología , Esquizofrenia/tratamiento farmacológico , Toxoplasmosis/tratamiento farmacológico , Ácido Valproico/farmacología , Adolescente , Adulto , Antimaníacos/administración & dosificación , Antipsicóticos/administración & dosificación , Disfunción Cognitiva/etiología , Método Doble Ciego , Sinergismo Farmacológico , Quimioterapia Combinada , Humanos , Persona de Mediana Edad , Risperidona/administración & dosificación , Esquizofrenia/complicaciones , Resultado del Tratamiento , Ácido Valproico/administración & dosificación , Adulto Joven
2.
Breast Cancer (Auckl) ; 8: 97-102, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24940070

RESUMEN

INTRODUCTION: A diagnosis of breast cancer regardless of the stage can be stressful, impact multiple spheres of life, and disrupt physical status, emotional and spiritual well-being, and personal relationships for the patient and family. In order to adapt, the patient ought to employ certain coping mechanisms. Individuals with terminal illness who utilize coping strategies have better quality of life compared to those who do not. PATIENTS AND METHODS: This study aimed to determine the strategies used by females with breast cancer to cope with such stress by using Brief COPE scale and the hospital anxiety and depression scale. The study included 56 female patients diagnosed with operable breast cancer at Mansoura Oncology Center before surgery. RESULTS: Large proportion of patients used acceptance, religion, and emotional support in coping with the stress of having breast cancer. Patients with depressive symptoms scored significantly higher venting while those with anxiety scored higher positive reframing, planning, and venting. CONCLUSION: Efforts should be made to encourage women with breast cancer to use coping strategies that have been found to be helpful (eg, acceptance, emotional support, distraction, and active coping strategies).

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA